Circulating miRNAs as new blood-based biomarkers for solid cancers

RÉDOVÁ, Martina, Jiří ŠÁNA and Ondřej SLABÝ. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncology. London: Future Medicine Ltd., 2013, vol. 9, No 3, p. 387-402, 6 pp. ISSN 1479-6694. Available from: https://dx.doi.org/10.2217/FON.12.192.

Basic information

• Original name: Circulating miRNAs as new blood-based biomarkers for solid cancers
• Authors: RÉDOVÁ, Martina (203 Czech Republic, belonging to the institution), Jiří ŠÁNA (203 Czech Republic, belonging to the institution) and Ondřej SLABÝ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: Future Oncology, London, Future Medicine Ltd. 2013, 1479-6694.

Other information

• Original language: English
• Type of outcome: Article in a journal
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• Impact factor: Impact factor: 2.611
• RIV identification code: RIV/00216224:14740/13:00065587
• Organization unit: Central European Institute of Technology
• Doi: http://dx.doi.org/10.2217/FON.12.192
• UT WoS: 000315966900013
• Keywords in English: biomarkers; breast cancer; colorectal cancer; lung cancer; miRNA; plasma; prostate cancer; serum
• Tags: rivok
• Tags: International impact, Reviewed

Abstract

miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.

Links

• ED1.1.00/02.0068, research and development project: Name: CEITEC - central european institute of technology
• NT13549, research and development project: Name: Vytvoření diagnostické sady cirkulujících mikroRNA pro neinvazivní časnou diagnostiku a sledování pacientů s kolorektálním karcinomem